



Human TNF- α ELISA

Catalog Number EA-0203

(For Research Use Only)

Introduction

Tumour Necrosis Factor alpha (TNF α), is an inflammatory cytokine produced by macrophages/monocytes during acute inflammation and is responsible for a diverse range of signaling events within cells, leading to necrosis or apoptosis. The protein is also important for angiogenesis that is critical to the growth, progression, and metastasis of solid tumors (1). Furthermore, TNF α is associated with obesity. It is chronically elevated in adipose tissues of obese rodents and humans and may represent an important link between obesity and insulin resistance (2-6). In both obese mice and humans, TNF α is overexpressed in adipose tissue. TNF α inhibits insulin signaling, at least in part by blocking insulin receptor tyrosine kinase activity and inducing serine phosphorylation of insulin receptor substrate-1 (IRS-1) (7). However, it is unclear what the physiological stimulator of TNF- α production by adipocyte during obesity is and how IRS-1 inhibits the tyrosine kinase activity of the insulin receptor after TNF- α treatment of the cells. A better understanding of the connection(s) between the TNF- α and the insulin signaling pathways could be important to find a cure for the state of insulin resistance observed during obesity.

Principle of the assay

TNF- α ELISA is based on the principle of a solid phase enzyme-linked immunosorbent assay. The assay utilizes a mouse anti-human TNF- α antibody for immobilization on the microtiter wells and goat anti-human TNF- α antibodies along with streptavidin conjugated to horseradish peroxidase (HRP) for detection. The test sample is allowed to react simultaneously with the two antibodies, resulting in the TNF- α molecules being sandwiched between the solid phase and enzyme-linked antibodies. After incubation, the wells are washed to remove unbound-labeled antibodies. A HRP substrate, TMB, is added to result in the development of a blue color. The color development is then stopped with the addition of Stop Solution changing the color to yellow. The concentration of TNF- α is directly proportional to the color intensity of the test sample. Absorbance is measured spectrophotometrically at 450 nm.




Diagram of ELISA

Materials provided with the kit

- 96 well microplate coated with a mouse anti-human TNF- α antibody (4°C).
- Biotin labeled goat anti-human TNF- α antibodies (45 μ g/ml) (-20°C).
- Streptavidin-HRP conjugate (4°C).
- Recombinant TNF- α standard (290ng/ml) (-20°C).
- 1X Diluent blocking buffer (4°C).
- 5X Assay wash buffer (RT)
- Substrate (4°C).
- Stop Solution (4°C).

Material required but not provided

- Microplate reader capable of measuring absorbance at 450 nm
- Deionized or distilled water.

Reagent preparation before starting experiment

- Dilute the 5x Assay wash buffer to 1x buffer
40ml 5x Assay wash buffer
160ml ddH₂O
- Dilute 290 times of human recombinant TNF- α (290ng/ml) with 1X Diluent buffer to 1000pg/ml and then 2-fold serial dilutions.
- Dilute 400 times of biotin labeled goat anti-human TNF- α with 1X Diluent buffer before use.
- Dilute 200 times of streptavidin-HRP with 1X Diluent buffer before use.

Assay procedure

1. Cut the sealing film over the plate and remove it from the desired number of well strips. Make sure the rest of wells are well sealed.
2. Add 100 μ l of Standard, control, or sample per well and incubate for 1 hour at room temperature with gentle shaking.
3. Aspirate each well and wash by adding 200 μ l of 1X Assay wash buffer. Repeat the process three times for a total of three washes. Complete removal of liquid at each wash. After the last wash, remove any remaining liquid by inverting the plate against clean paper towels.
4. Add 100 μ l of diluted biotin-labeled goat anti-human TNF- α antibody to each well and incubate for 1 hour at room temperature with gentle shaking.
5. Repeat the aspiration/wash as in step 3.
6. Add 100 μ l of diluted streptavidin-HRP conjugate to each well and incubate for 45 min at room temperature with gentle shaking.
7. Repeat the aspiration/wash as in step 3.
8. Add 100 μ l substrate to each well and incubate for 5-30 minutes.
9. Add 50 μ l of Stop solution to each well. The color in the wells should change from blue to yellow.
10. Determine the optical density of each well with a microplate reader at 450 nm within 30 minutes.

References

1. Folkman, J. 1971. Tumour angiogenesis: therapeutic implications. *N. Engl. J. Med.* 285, 1182–1186.
2. Hotamisligil, GS, Shargill, NS, and Spiegelman, BM 1993 Adipose expression of tumor necrosis factor- α : Direct role in obesity-linked insulin resistance. *Science* 259:87-90.
3. Hotamisligil, GS, Arner, P, Caro, JF, Atkinson, RL, Spiegelman, BM 1995 Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. *J. Clin. Invest.* 95:2409-2415.
4. Kern, PA, Saghizadeh, M, Ong, JM, Bosch, RJ, Deem, R, and Simsolo, RB 1995 The expression of tumor necrosis factor in human adipose tissue. *J. Clin. Invest.* 95:2111-2119.
5. Sethi, J. K. & Hotamisligil, G. S. 1999 The role of TNF alpha in adipocyte metabolism. *Semin. Cell Dev. Biol.* 10, 19–29.
6. Peraldi, P. & Spiegelman, B. 1998 TNF- α and insulin resistance: Summary and future prospects *Mol. Cell Biochem.* 182, 169–175.
7. Hotamisligil, GS, Peraldi, P, Budavari, A, Ellis, R, White, MF, and Spiegelman, BM 1996 IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. *Science* 271:665-8.

Example of standard curve

